C4 Therapeutics reports 53% response rate in myeloma drug trial

June 11, 2026 7:00 AM

C4 Therapeutics Inc. (NASDAQ: CCCC) reported results from its Phase 1 trial of cemsidomide for treating relapsed/refractory multiple myeloma. The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found